Brief: Theseus Pharmaceuticals Presents Preclinical Data Characterizing The-349, Its Fourth-Generation Egfr Inhibitor In Development For Nsclc, At The 34Th Eortc-Nci-Aacr Symposium
26/10/2022 12:12
Oct 26 (Reuters) - Theseus Pharmaceuticals Inc THRX.O :
* THESEUS PHARMACEUTICALS PRESENTS PRECLINICAL DATA
CHARACTERIZING
THE-349, ITS FOURTH-GENERATION EGFR INHIBITOR IN DEVELOPMENT FOR
NSCLC, AT THE 34TH EORTC-NCI-AACR SYMPOSIUM
* THESEUS PHARMACEUTICALS INC - IND SUBMISSION TO US FDA
ANTICIPATED IN H2 2023
Source text for Eikon: ID:nPn2l0Bpfa
Further company coverage: THRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theseus Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Cidara Therapeutics, Senti Bio, Lumentum Holdings
U.S. STOCKS ON THE MOVE-Newmont Corp, Ansys, Karuna Therapeutics
Theseus Pharma rises as Concentra Biosciences agrees to take it private
Brief: Theseus Pharmaceuticals To Be Acquired by Concentra Biosciences
Brief: Theseus Pharmaceuticals Inc Says As Part Of A Reduction In Workforce, Co Terminated Employment Of Timothy P. Clackson, Co's CEO, Effective As Of Dec 7